TW200829234A - Antrodia camphorata isophorone extract - Google Patents
Antrodia camphorata isophorone extract Download PDFInfo
- Publication number
- TW200829234A TW200829234A TW096100680A TW96100680A TW200829234A TW 200829234 A TW200829234 A TW 200829234A TW 096100680 A TW096100680 A TW 096100680A TW 96100680 A TW96100680 A TW 96100680A TW 200829234 A TW200829234 A TW 200829234A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- growth
- tumor cells
- inhibiting
- cells
- Prior art date
Links
- 241001486992 Taiwanofungus camphoratus Species 0.000 title claims abstract description 36
- 239000000284 extract Substances 0.000 title claims abstract description 33
- HJOVHMDZYOCNQW-UHFFFAOYSA-N isophorone Chemical compound CC1=CC(=O)CC(C)(C)C1 HJOVHMDZYOCNQW-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 60
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 30
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 30
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 30
- 230000012010 growth Effects 0.000 claims abstract description 26
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 25
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 230000004614 tumor growth Effects 0.000 claims abstract 4
- 210000004027 cell Anatomy 0.000 claims description 70
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 208000014018 liver neoplasm Diseases 0.000 claims description 17
- 201000007270 liver cancer Diseases 0.000 claims description 16
- 239000003960 organic solvent Substances 0.000 claims description 15
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 230000004565 tumor cell growth Effects 0.000 claims description 7
- 241000123370 Antrodia Species 0.000 claims description 6
- 235000003130 Arctium lappa Nutrition 0.000 claims description 6
- 235000008078 Arctium minus Nutrition 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 6
- 239000006286 aqueous extract Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 4
- 235000006533 astragalus Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims 2
- 241000723346 Cinnamomum camphora Species 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 229960000846 camphor Drugs 0.000 claims 2
- 229930008380 camphor Natural products 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 240000005528 Arctium lappa Species 0.000 claims 1
- 241001061264 Astragalus Species 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims 1
- 229960003132 halothane Drugs 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 210000004233 talus Anatomy 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 235000013402 health food Nutrition 0.000 abstract description 3
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 abstract description 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- CWCLGQHRPGRDDH-UHFFFAOYSA-N 2-(3,7,11-trimethyldodeca-2,6,10-trienyl)cyclohex-2-en-1-one Chemical compound CC(=CCC=1C(CCCC1)=O)CCC=C(CCC=C(C)C)C CWCLGQHRPGRDDH-UHFFFAOYSA-N 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 51
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 19
- 229930012538 Paclitaxel Natural products 0.000 description 19
- 229960001592 paclitaxel Drugs 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 150000003648 triterpenes Chemical class 0.000 description 7
- -1 vitamin B Natural products 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 241000208843 Arctium Species 0.000 description 5
- 238000009098 adjuvant therapy Methods 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000012139 lysis buffer Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 4
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- 229960004844 lovastatin Drugs 0.000 description 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 241000239226 Scorpiones Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000010304 tumor cell viability Effects 0.000 description 3
- DVORYMAGXQGBQK-UHFFFAOYSA-N zhankuic acid A Natural products CC12CCC(=O)C(C)C1CC(=O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 DVORYMAGXQGBQK-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- JXBSHSBNOVLGHF-UHFFFAOYSA-N 2,6,10-trimethyldodeca-2,6,10-triene Chemical compound CC=C(C)CCC=C(C)CCC=C(C)C JXBSHSBNOVLGHF-UHFFFAOYSA-N 0.000 description 2
- SDYJYMBMSYYZIC-UHFFFAOYSA-N 7,7-dimethyl-4-methylidene-3,3a,5,6,6a,8,9,10-octahydrobenzo[h][2]benzofuran-1-one Chemical compound C=C1CCC2C(C)(C)CCCC32C(=O)OCC31 SDYJYMBMSYYZIC-UHFFFAOYSA-N 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- ONFPYGOMAADWAT-OXUZYLMNSA-N Dehydroeburicoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)CC[C@@]4(C)C3=CC[C@H]21 ONFPYGOMAADWAT-OXUZYLMNSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229960003750 ethyl chloride Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930009674 sesquiterpene lactone Natural products 0.000 description 2
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229930188837 zhankuic acid Natural products 0.000 description 2
- NDNKBYRXHKLSJQ-UXYVAYPWSA-N (2r)-2-[(3s,5r,10s,13r,14r,15s,17r)-15-acetyloxy-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)C[C@H](OC(C)=O)[C@@]4(C)C3=CC[C@H]21 NDNKBYRXHKLSJQ-UXYVAYPWSA-N 0.000 description 1
- DVORYMAGXQGBQK-HPRYJKPLSA-N (2s,6r)-2-methyl-3-methylidene-6-[(4s,5s,10s,13r,14r,17r)-4,10,13-trimethyl-3,7,11-trioxo-1,2,4,5,6,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptanoic acid Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 DVORYMAGXQGBQK-HPRYJKPLSA-N 0.000 description 1
- TWISSXUWVGIUBP-UHFFFAOYSA-N (4alpha,7beta)-7-Hyddroxy-4-methyl-3,11-dioxoergosta-8,24(28)-dien-26-oic acid Natural products CC12CCC(=O)C(C)C1CC(O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 TWISSXUWVGIUBP-UHFFFAOYSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- PMHCHLYGCHPBEC-CYFVRWTGSA-N (6R)-2-methyl-3-methylidene-6-[(4S,10S,13R,17R)-4,10,13-trimethyl-3,11-dioxo-2,4,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid Chemical compound O=C1[C@H](C2CCC=3C4=CC[C@H]([C@@H](CCC(C(C(=O)O)C)=C)C)[C@]4(CC(C=3[C@]2(CC1)C)=O)C)C PMHCHLYGCHPBEC-CYFVRWTGSA-N 0.000 description 1
- ZPSJWLSADLCKBZ-GIMPTUAXSA-N (6r)-6-[(4s,7s,10s,13r,17r)-7-hydroxy-4,10,13-trimethyl-3,11-dioxo-2,4,5,6,7,12,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methyl-3-methylideneheptanoic acid Chemical compound C([C@@]12C)CC(=O)[C@@H](C)C1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC=C21 ZPSJWLSADLCKBZ-GIMPTUAXSA-N 0.000 description 1
- CRSBERNSMYQZNG-UHFFFAOYSA-N 1 -dodecene Natural products CCCCCCCCCCC=C CRSBERNSMYQZNG-UHFFFAOYSA-N 0.000 description 1
- RZTDESRVPFKCBH-UHFFFAOYSA-N 1-methyl-4-(4-methylphenyl)benzene Chemical group C1=CC(C)=CC=C1C1=CC=C(C)C=C1 RZTDESRVPFKCBH-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- NDNKBYRXHKLSJQ-UHFFFAOYSA-N 15alpha-acetyldehydrosulphurenic acid Natural products CC(C)C(=C)CCC(C1CC(OC(=O)C)C2(C)C3=CCC4C(C)(C)C(O)CCC4(C)C3=CCC12C)C(=O)O NDNKBYRXHKLSJQ-UHFFFAOYSA-N 0.000 description 1
- WTSUWKBKPMVEBO-UHFFFAOYSA-N 4alpha-4-Methyl-3,11-dioxoergosta-8,24(28)-dien-26-oic acid Natural products CC12CCC(=O)C(C)C1CCC1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 WTSUWKBKPMVEBO-UHFFFAOYSA-N 0.000 description 1
- WAAWMJYYKITCGF-WTPIMUJOSA-N 5alpha-ergostane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C)C(C)C)[C@@]2(C)CC1 WAAWMJYYKITCGF-WTPIMUJOSA-N 0.000 description 1
- 244000183611 Acacia suaveolens Species 0.000 description 1
- PMHCHLYGCHPBEC-UHFFFAOYSA-N Antcin E Natural products CC(CCC(=C)C(C)C(=O)O)C1CC=C2C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)C4CC3 PMHCHLYGCHPBEC-UHFFFAOYSA-N 0.000 description 1
- ZPSJWLSADLCKBZ-UHFFFAOYSA-N Antcin F Natural products CC12CCC(=O)C(C)C1CC(O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CC=C21 ZPSJWLSADLCKBZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YBSIPTHESHMQDU-UHFFFAOYSA-N C(CCCCCCCCC)C(=CC)CCC=C(CCC=C(C)CCCCCCCCCC)CCCCCCCCCC Chemical compound C(CCCCCCCCC)C(=CC)CCC=C(CCC=C(C)CCCCCCCCCC)CCCCCCCCCC YBSIPTHESHMQDU-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- PONMMBJIVKHXIF-UHFFFAOYSA-N C1(C=CCCC1)=O.CC(=CC)CCC=C(CCC=C(C)C)C Chemical compound C1(C=CCCC1)=O.CC(=CC)CCC=C(CCC=C(C)C)C PONMMBJIVKHXIF-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 101150000595 CLMP gene Proteins 0.000 description 1
- JVNQXVNESRQHFI-UHFFFAOYSA-N COC1=C(C=C(C=2OCOC21)OC)S Chemical compound COC1=C(C=C(C=2OCOC21)OC)S JVNQXVNESRQHFI-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 241000386860 Cinnamomum micranthum Species 0.000 description 1
- ONFPYGOMAADWAT-UHFFFAOYSA-N Dehydroeburicolic acid Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC4(C)C3=CCC21 ONFPYGOMAADWAT-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101100382322 Drosophila melanogaster Acam gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- ZWMDJBNGXKAIRO-UHFFFAOYSA-N Methyl antcinate H Natural products CC12CCC(O)C(C)C1CC(=O)C1=C2C(=O)C(O)C2(C)C(C(C)CCC(=C)C(C)C(=O)OC)CCC21 ZWMDJBNGXKAIRO-UHFFFAOYSA-N 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TXEJUZMIQVTZHO-UHFFFAOYSA-N Zhankuic acid B Natural products CC12CCC(O)C(C)C1CC(=O)C1=C2C(=O)CC2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 TXEJUZMIQVTZHO-UHFFFAOYSA-N 0.000 description 1
- LVFHKUZOQUATIE-UHFFFAOYSA-N Zhankuic acid C Natural products CC12CCC(O)C(C)C1CC(=O)C1=C2C(=O)C(O)C2(C)C(C(CCC(=C)C(C)C(O)=O)C)CCC21 LVFHKUZOQUATIE-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- WTSUWKBKPMVEBO-QNMMDLTMSA-N antcin A Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CCC1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 WTSUWKBKPMVEBO-QNMMDLTMSA-N 0.000 description 1
- TWISSXUWVGIUBP-IRXLFGEOSA-N antcin C Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)[C@H](C)C(O)=O)C)CC[C@H]21 TWISSXUWVGIUBP-IRXLFGEOSA-N 0.000 description 1
- ZPSJWLSADLCKBZ-BJLSYBTBSA-N antcin F Natural products C[C@H](CCC(=C)[C@H](C)C(=O)O)[C@H]1CC=C2C3=C(C(=O)C[C@]12C)[C@@]4(C)CCC(=O)[C@@H](C)[C@@H]4C[C@@H]3O ZPSJWLSADLCKBZ-BJLSYBTBSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OQUUTERJWTYTHP-UHFFFAOYSA-N butanedioate;1h-tetrazol-1-ium Chemical compound [NH2+]1C=NN=N1.[NH2+]1C=NN=N1.[O-]C(=O)CCC([O-])=O OQUUTERJWTYTHP-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- DVXFDXIVWQWLIU-UHFFFAOYSA-N dehydroeburiconic acid Natural products CC1(C)C(=O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC4(C)C3=CCC21 DVXFDXIVWQWLIU-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229940069096 dodecene Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- ZQIOPEXWVBIZAV-ZKYCIREVSA-N lanostane Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)[C@@H]1[C@@H]2[C@]2(C)CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 ZQIOPEXWVBIZAV-ZKYCIREVSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- ZWMDJBNGXKAIRO-PRBDMEKXSA-N methyl antcinate H Chemical compound C([C@@]12C)C[C@@H](O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)[C@H](O)[C@]2(C)[C@@H]([C@H](C)CCC(=C)C(C)C(=O)OC)CC[C@H]21 ZWMDJBNGXKAIRO-PRBDMEKXSA-N 0.000 description 1
- 229930183875 methylantcinate Natural products 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003429 steroid acids Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
- DVORYMAGXQGBQK-QCMFUGJUSA-N zhankuic acid A Chemical compound C([C@@]12C)CC(=O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 DVORYMAGXQGBQK-QCMFUGJUSA-N 0.000 description 1
- TXEJUZMIQVTZHO-JNXQNPAGSA-N zhankuic acid B Chemical compound C([C@@]12C)C[C@@H](O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 TXEJUZMIQVTZHO-JNXQNPAGSA-N 0.000 description 1
- LVFHKUZOQUATIE-NIQDNRFFSA-N zhankuic acid C Chemical compound C([C@@]12C)C[C@@H](O)[C@@H](C)[C@@H]1CC(=O)C1=C2C(=O)[C@H](O)[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C(O)=O)C)CC[C@H]21 LVFHKUZOQUATIE-NIQDNRFFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/02—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains containing only carbon and hydrogen atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
200829234 九、發明說明: 【發明所屬之技術領域】 本發明係關於一種新穎化合物,尤其係關於一種由牛 樟芝萃取物中所分離純化之化合 物及其於抑制腫瘤細胞生長之應用。 【先前技術】 牛樟芝(ca/wp/zoraiflr),又稱樟芝、牛樟兹、 紅樟、紅樟芝、樟菰或樟窟内菰等,為臺灣特有種真菌, 只生長於臺灣山區海拔45〇〜2〇〇〇公尺間之牛樟樹 (Cz/wamowm tme/zim/ Hay )的中空腐朽心材内壁上,因 此是由樹幹内面生長出子實體。牛樟樹目前主要分佈於桃 園:南投等山區,由於牛樟樹是台灣數量極為稀少的保育 類樹種,加上人為的盜伐,使得寄生於其中方能生長之野 生牛樟芝數量更形稀少,且由於其生長相當緩慢,^長期 亦僅在六月至十月之間,因此價格非常昂貴。 丁评之1于灵體為多年生,無柄,呈木栓質至 狀、鐘狀、馬蹄狀或塔狀。初0_ 、生於木龍面,之後其前齡略為捲她起,而 =2纹板狀)或如鐘乳石狀。牛樟芝頂部表面呈 胳色,具不明顯的皺紋,有光澤,邊緣平而鈍, 腹面則為橘紅色或局部黃色,並有許多域。 200829234 +立Γ:,具有強烈的黃樟香氣’其曬乾後褪色成 -$古’民間將其用作解毒、保肝、抗癌之草 牛敎如同-般食_的蕈_,具有許多複雜的成 刀已去的生理/舌性成分中,包括:多醣體 (P〇lysaccharides’如:沒_萄聚醣)、三箱類化合物 ㈣e—)、超氧歧化酶(sup_ide dismutase ,SOD)、
腺苷(adenosine)、蛋白質(含免疫球蛋白)、維生素(如:維 生素B、終鹼酸)、微量元素(如:#5、構及鍺等)、核 酸、凝集素、胺基酸、固醇類、木質素以及金壓穩定物質 (如·ιηί〇(1^ acid)等,這些生理活性成分被認為具有抗 腫瘤、增加免疫能力、抗過敏、抑制血小板凝集、抗病毒、 抗細菌、抗尚血壓、降血糖、降膽固醇以及保護肝臟等功 牛樟芝眾多成分中以三萜類化合物被研究的最多, 三萜類化合物是由三十個碳元素結合成六角形或五角形 天然化合物之總稱’牛樟芝所具之苦味即主要來自三萜類 此成分。1995年時,Cherng等人發現牛樟芝子實體萃取 物中含有三種新的以麥角留烧(ergostane)為骨架的三萜 類化合物:antcin A、antcin B 與 antcin C( Cherng,I. H·,and Chiang, H. C. 1995. Three new triterpenoids from Antrodia J· Nat· Prod· 58:365-371 )。Chen 等人以乙醇 萃取樟芝子實體後發現zhankuic acid A、zhankuic acid B 及zhankuic acid C等三種三萜類化合物(Chen,C· H·,and Yang, S. W. 1995. New steroid acids from Antrodia 6 200829234 cinnamomea, - a fungus parasitic on Cinnamomum micranthum. L Nat. Prod. 58:1655-1661)。此外,Chiang 等人於1995年也由子實體萃取物中發現另外三種分別 為倍半萜内醋(sesquiterpene lactone)與兩種雙酴類衍生 物的新三萜類化合物,此即antrocin,4,7-二曱氧基-5-曱 基-1,3-苯並二氧環(4,7-dimethoxy-5-methy_l,3-benzodioxole)與 2,2’,5,5’_四甲氧基_3,4,3,,4丨_雙·亞甲二氧 基-6,6’_ 二甲基聯苯(2,2’,5,5?七以11^1;11€^-3,4,3丨,4’·!^· ( methylenedioxy-6,6f_ dimethylbiphenyl) (Chiang,H· C·,Wu, D· P·,Cherng, I· W·,and Ueng,C· Η· 1995· A sesquiterpene lactone,phenyl and biphenyl compounds from Antrodia czVwflmoweo· Phytochemistry· 39:613_616)。到了 1996 年, Cherng等人以同樣分析方法再度發現四種新的三箱類化 合物:antcin E、antcin F、methyl antcinate G、methyl antcinate H ( Cherng,Ι· H·,Wu,D· P·,and Chiang,Η· C· 1996. Triteroenoids from Antrodia cinnamomea· i Phytochemistry· 41:263-267);而 Yang 等人則發現了二種 以麥角甾烧為骨架的新化合物zhankuic acid D、zhankuic acid E,和三種以羊毛甾烧(lanostane)為骨架的新化合 物·· 15 α -乙醯-去氫硫色多孔菌酸(15 α -acetyl-dehydrosulphurenic acid )、去氫齒孔酸 (dehydroeburicoic acid )與去水硫色多孔菌酸 (dehydrasulphurenic acid) ( Yang,S· W·,Shen,Y· C·,and Chen, C, H. 1996. Steroids and triterpenoids of Antrodia 200829234 cinnamomea - a fungus parasitic on Cinnamomum
Phytochemistry· 41:1389_ 1392)。雖然由目前 諸多之實驗可得知牛樟芝萃取物具有抑癌之功效(如前述
Chen ( 1995)),但究為何種有效成分可達到抑制腫瘤 細胞效果之研究,目前則仍處於試驗階段,並未有具體之 有效成分發表,故若能將該萃取物進一步純化分析,找出 其真正有效抑癌成分,對於人類癌症之治療實將產生莫大 的助益。 ^ 【發明内容】 為明瞭牛樟芝萃取物中究竟是何成分具有抑癌之效 果,本發明由牛樟芝萃取物中分離純化出具式(1)結構式 之新穎化合物; ^
氫基 3 ’ R3係氫基、曱基或(CH2)m_CH3,m= 基或…n2)m-CH3,R3係氫基、 12 ; n= 1 〜12 0 較佳者為如下所示式(2) 如式(1)結構式之化合物中, 之化合物: 200829234
(2) 式(2)之化合物,其化學名為4-羥基-2,3-二甲氧基_6_ 甲基-5 (3,7,11-三甲基-2,6,10-十二碳三烯)_2_環己烯酉同 (4_hydroxy_2,3_dimethoxy-6-methy-5(357,ll-trimethyl_ci0 deca-2?6510-trienyl)-cyclohex-2-enone ),分子式為 C24H38〇4,夕卜觀為淡黃色粉末狀,分子量為390。 " 本發明中式(1)、式(2)之化合物係分離純化自牛棒芝 水萃取物或有機溶劑萃取物,有機溶劑可包括醇類(例如 曱醇、乙醇或丙醇)、酯類(例如乙酸乙酯)、烧類(例 如己烧)或鹵烷(例如氯甲烷、氯乙烷),但並不以此為 限,其中較佳者為醇類,更佳者為乙醇。 藉由前述化合物,本發明係將其應用於抑制腫瘤細 胞生長上,使能進一步應用於治療癌症之醫藥組成份中, 增益癌症之治療效果。本發明化合物得應用之範圍包括對 於乳癌腫瘤細胞、職_細胞與攝獅癌_細胞等細 胞之生長產生抑制效果,使該等腫瘤細胞無法迅速生長, 進而抑制腫瘤之增生,延緩腫瘤之惡化,因此,可進一步 利用於乳癌、肝癌與攝護腺癌等癌症之治療。 另一方面,本發财亦可將式⑴或/與式(2)之化合物 利用於治療乳癌、肝颇攝護腺料㈣域物之成分 200829234 制該等腫瘤細胞的生長。前述醫藥組成物除包 上可垃里之式⑴或/與式(2)之化合物外,尚可包括藥學 "、文的载體。載體可為賦形劑(如水)、填充劑(如 S或&粉)、黏合劑(如纖維素衍生物)、稀釋劑、崩 从,、、吸收促進劑或甜味劑,但並未僅限於此。本發明醫 樂組成物可依—般習知藥學之製備方法生產製造,將式(1) 或/與^(2)有效成分劑量與一種以上之載體相混合,製儐 出所舄之知彳型,此劑型可包括錠劑、粉劑、粒劑、膠囊威 其他液體製劑,但未以此為限。 此外,由於本發明中之化合物同時具有抗氧化滲 性,因此亦可將之添加於保健食品、飲食品、醫藥品、化 妝品當中,藉由其抗氧化能力達到預防心血管疾病或避免,細 胞突變等效用,使助益於施用人體之健康。 以下將配合圖式進一步說明本發明的實施方式,下述 所列舉的實施例係用以闡明本發明,並非用以限定本發明 之範圍,任何熟習此技藝者,在不脫離本發明之精神和範 圍内,當可做些許更動與潤飾,因此本發明之保護範圍當 視後附之申請專利範圍所界定者為準。 【實施方式】 首先取牛樟芝(如的出acamp/zorofia)菌絲體、子實 體或二者之混合物,利用習知萃取方式,以水或有機溶劑 200829234 進仃萃取’藉以取得牛樟芝水萃取物或有機㈣丨萃取物。 其中,有機溶劑可包括醇類(例如甲醇、乙醇或丙醇)、 ,類(例,乙酸乙醋)、鋪(例如己燒)或鹵烧(例如 亂曱炫、氯乙烧),但並不以此為限。其中較佳者為醇類, 更佳者為乙醇。 經萃取過後之牛樟芝水萃取物或有機溶劑萃取物, 可進一步藉由高效液相層析加以分離純化,之後再對每一 分液(fraction)進行抑癌效果的測試。最後,則針對具 ^癌效果之分液進行成分分析,將可能產生抑癌效果的成 刀再刀別進一步做不同癌症腫瘤細胞之抑制效果測試。最 終即發現本發财如式⑴/式⑺之化合物係具有抑制不 同癌症腫瘤細胞生長之效果,且該化合物經與習知文獻比 對,並未曾發現於牛樟芝中,因此係一新穎之化合物。 為方便說明本發明,以下將以式(2)之扣經基_2,3_二甲 氧基-6-甲基-5 (3,7,11-三甲基-2,6,10-十二碳三婦)·2-環 己烯酮化合物進行說明。此外,為證實4_羥基_2,3_二甲 氧基_6_甲基-5 (3,7,11-三甲基-2,6,10,十二碳三烯)-2-環 己烯酮化合物對腫瘤細胞生之抑制效果,本發明中係以 ΜΤΤ分析法,根據美國國家癌症研究所(National Cancer Institute,NCI)抗腫瘤藥物篩檢模式,對包括乳癌、肝癌 與攝護腺癌等腫瘤細胞進行細胞存活率之測試。由該些測 試證實,4·羥基·2,3-二甲氧基-6-甲基-5 (3,7,11-三甲基 _2,6,10_十二碳三婦)_2_環己烯酮對於乳癌腫瘤細胞(包 π 200829234 括=與MDA_MB_231)、肝癌彻細胞(包括~ ηπ Γμ /2)與攝護腺癌膜瘤細皰(包括LNCaP與 生長半抑可降低其存活率’相對之下並可同時降低 生長+抑制率所需濃度(即❿值),因此得藉由㈣ 基-2,3·二甲氧基冬甲基_5 ( 3Λ1 k甲基以鼻十二碳 二炸)_2·環己相,應麟包括乳癌、肝癌與攝護腺癌 等腫瘤細胞之生長抑制上,而進-步可彻於乳癌、肝癌 與攝護腺癌等癌症之治療。_前述實財式詳盡說明如 -| — · 實施例1 : 4-經基-2,3_一甲氧基_6_甲基_5( 3,7,11_三甲基_2,6,1〇_十二 碳三烯)-2•環己稀酮的分離 將100克左右之牛樟芝菌絲體、子實體或二者之混 合物’置入三角錐形瓶中,加入適當比例的水與醇類 (70%〜100%醇類水溶液),於20〜25°C下櫈拌萃取至少 1小時以上,之後以濾紙及〇·45 μιη濾膜過濾,收集萃取 液0 將前述收集之牛樟芝萃取液,利用高效能液相層析 儀(High Performance Liquid chromatography),以 RP18 的 層析管(column)進行分析,並以甲醇(A)及〇·ι%〜〇·5%醋 酸水溶液(Β)做為移動相(mobile phase)(其溶液比例係·· 0〜10分鐘,B比例為95%〜20% ; 1〇〜20分鐘,B比例為 20%〜10%; 20〜35分鐘’ B比例為1〇%〜1〇%; 35〜40分鐘, 12 200829234 B比例為10〇/。〜95〇/〇),在每分鐘! ml之速度下 _ 時以紫外-可見光全波長偵測器分析。 同 將25分鐘至30分鐘之沖提液收集濃縮即可彳卩*主 色粉末狀之固體產* ’特4-經基_2,3_二甲氧基:犬頁 -5 (3,7,11_三曱基_2A1G_十:碳三婦)_2_環己_ = 分析,其分子式為C24H38〇4,分子量39〇,熔點(功‘ 為48°C〜52°C。核磁共振(NMR)分析值則如下二二)· f 々-NMR^CDClJWppm) : 1.5卜 1.67、1.7卜 1.75、i 94 2.03、2.07、2.22、2-25、3.68、4.05、5.07 與 5.14、 13C-NMR(CDC13) 5 (ppm) : 12.31、16.1、16.12、17 67 25.67、26.44、26.74、27.00、39.71、39.81、4.027、43 34 59.22、60.59、120.97、123.84、124.30、131.32、135 35 135·92、138·05、160.45 與 197·12。 經將4_羥基_2,3·二甲氧基-6-曱基_5 (3,7,11-三甲烏 -2,6,10-十二碳三烯)-2-環己烯酮與化學式資料庫比對 後’並未發現與前述相同之化合物結構,因此,此化合物 係一新穎且前所未見之化合物。 實施例2 : 體外抗乳癌腫瘤細胞之活性測試 為進一步測試實施例1中所發現化合物對腫瘤細跑 之抑制效果,本實施例將根據美國國家癌症研究所 (National Cancer Institute,NCI)抗腫瘤藥物篩檢模式, 13 200829234 首先取實施例1中所分離之4-羥基-2,3-二曱氧基-6-甲基 5 (3,7,11·三曱基-2,6,10-十二碳三烯)-2-環己烯_化合 物,加入MCF-7與MDA-MB-231人類腫瘤細胞培養液 中,進行腫瘤細胞存活性之測試。細胞存活性之測試可採 習知之MTT分析法進行分析,而MCF_7與MDA-MB-231 皆係人類之乳癌腫瘤細胞系。 MTT分析法是一種常見用於分析細胞增生(cell proliferation)、存活率(percent of viable cells)以及細 胞毒性(cytotoxicity)的分析方法。其中,]\4丁丁(3-[4,5-dimethylthiazol_2_yl]2,5_diphenyltetrazolium bromide )為一 黃色染劑,它可被活細胞吸收並被粒腺體中的琥珀酸四唾 還原酶(succinate tetrazolium reductase )還原成不溶水性 且呈藍紫色的formazan,因此藉由formazan形成與否, 即可判斷並計算細胞之存活率。 首先將人類乳癌細胞MCF-7與MDA-MB-231分別 於含有胎牛血清之培養液中培養24小時。將增生後之細 胞以PBS清洗一次,並以1倍之胰蛋白酶_EDTA處理細 胞,隨後於l,200rpm下離心5分鐘,將細胞沈澱並丟棄 上清液。之後加入10 ml的新培養液,輕微搖晃使細胞再 次懸浮,再將細胞分置於96孔微量盤内。測試時,分別 於每一孔内加入 30、10、3、1、0·3、〇·ι 與 0 03 μ§/ιη1 牛樟芝乙醇萃取物(對照組,未經純化分離之總萃取物) 以及4_經基_2,3_二甲氧基-6-曱基-5( 3,7,11-三甲基_2,6,10_ 200829234 十二碳三烯)-2-環己烯酮(試驗組),於37°c、5% C〇2 下培養48小時。其後,於避光的環境下於每一孔内加入 2·5 mg/ml的MTT,反應4小時後再於每一孔内加入1〇〇 μ1 的lysis buffer終止反應。最後以酵素免疫分析儀在57〇nm 吸光波長下測定其吸光值,藉以計算細胞的存活率,並推 异出其生長半抑制率所需濃度(即IC5()值),其結果如 表一所示。 表一:體外對乳癌腫瘤細胞存活率之測試結果 挫樣品_ ic5〇Ug/mn 對照組(加入牛樟芝萃取物) 11.132 25.812 MCF_7 MDA-MB-231 試驗組(加入式2) ~ —__,w ^ 夏— 由表一中可知,藉由4-羥基-2,3-二曱氧基_6_曱基_5 (3,7,11-三甲基_2,6,10_十二碳三烯)_2_環己缔綱的作 用’其對於MCF-7人類乳癌腫瘤細胞之ICs()值為〇852
Pg/ml’對於mda-MB-231人類乳癌腫瘤細胞之IC5g值則 為1.031 pg/m卜相較於牛樟芝萃取混合物所測得之忙 值係低的多,因此可證實牛樟芝萃取物中之4__美 一甲氧基-6-曱基-5( 3,7,11_三曱基-2,6,10-十二碳三烯 環己烯_確實能夠利用於乳癌腫瘤細胞生長之抑制。β 15 200829234 實施例3 : 體外對乳癌腫瘤細胞辅助治療之活性測試 本測試同樣係根據美國國家癌症研究所的體外篩檢 模式進行測試。首先,取人類乳癌細胞MCF-7與 MDA-MB-231 ’分別於含有胎牛血清之培養液中培養24 小時後,將增生後之細胞以PBS清洗一次,並以1倍之 胰蛋白酶-EDTA處理細胞,隨後於i,2〇〇 rpm下離心5分 鐘’將細胞沈殿並丟棄上清液。之後加入1〇 ml的新培養 液,輕微搖晃使細胞再次懸浮。測試前,先加入〇 〇〇17 pg/ml紫杉醇(Taxol)處理細胞72小時,再將細胞分置 於96孔微量盤内,之後分別於每孔内加入〇μ§/πι1 (對照 組),30、10、3、1、0·3、0.1 與 〇·〇3 pg/ml 實施例 1 中 所分離之4_羥基-2,3_二甲氧基-6-曱基-5 (3,7,11-三甲基 -2,6,10-十二碳三烯)-2·環己烯酮(試驗組),於37°C、 5% C〇2下培養48小時。其後,於避光的環境下於每一 孔内加入2.5mg/ml的MTT,反應4小時後於每一孔内加 入100 μΐ的lysis buffer終止反應。最後以酵素免疫分析 儀在570nm吸光波長下測定其吸光值,藉以計算細胞的 存活率,並推算出其生長半抑制所需濃度(即IC5()值), 其結果如表二所示。 表二··體外對乳癌腫瘤細胞經紫杉醇辅助治療後抑制之測 試結果 16 200829234 測試樣品 結果 對照組 細胞存活率(%) MCF-7 (0.0017 μδ/ηι1 Taxol) 65 土 1 MDA-MB-231 (0.0017 pg/ml Taxol) 76土 3 試驗組 IC50 (pg/ml) MCF-7 (0.0017 pg/ml Taxol+式 2) 0.009 MDA-MB_231 (0.0017 pg/ml Taxol+式 2) 0.011 由表二中可知,透過紫杉醇之協同作用,4-經基-2,3-二甲氧基-6-曱基_5 ( 3,7,11-三甲基-2,6,l〇-十二碳三烯)_2一 環己細酮對於MCF-7人類乳癌腫瘤細胞之ic5G值降為 0.009吨嵐,對於MDA-MB_231人類乳癌腫瘤細胞之冗5〇 值亦降為約0.011 pg/m卜因此可證實牛樟芝萃取物中之 4-髮基_2,3_二曱氧基_6_曱基-5 (3,7,11-三甲基_2,6,10·十二 石反二烯)_2_環己烯酮確實能夠利用於乳癌腫瘤細胞生長之 抑制’衫料彡醇之協同制下,有更佳之抑制效果。 實施例4 : 體外抗肝癌腫瘤細胞之活性測試 “本測試亦係根據美_家癌症研究所抗腫瘤藥物筛 檢模式進行’將實關1巾所分離之4_減_2,3_二甲氧基 -5 (3,7,11_三曱基_2,6抓十二碳三婦> 環己自 =二加入Hep 3B與Hep G2人類肝癌腫瘤細胞培養 、之進仃培養,藉以進行腫瘤細胞存活性之測試。 17 200829234 首先將人類肝癌細胞Hep 3B與Hep G2分別於含有 胎牛血清之培養液中培養24小時。將增生後之細胞以 PBS清洗一次,並以1倍之胰蛋白酶-EDTA處理細胞, 隨後於l,200rpm下離心5分鐘,將細胞沈澱並丟棄上清 液。之後加入10 ml的新培養液,輕微搖晃使細胞再次懸 浮’再將細胞分置於96孔微量盤内。測試時,分別於每 孔内加入 30、10、3、1、0·3、0.1 與 〇·〇3 pg/ml 之牛樟 芝乙醇萃取物(對照組,未經純化分離之總萃取物)以及 3〇、10、3、1、〇·3、〇·1 與 0.03 pg/ml 之 4·羥基-2,3-二甲 氧基_6_甲基_5 (3,7,11-三曱基-2,6,10-十二碳三烯)_2•環己 烯酮(試驗組),於37°C、5% C02下培養48小時。其 後’於避光的環境下於每一孔内加入2.5 mg/ml的MTT, 反應4小時後再於每一孔内加入1〇〇 μΐ的lysis buffer終 止反應。最後以酵素免疫分析儀在570 nm吸光波長下測 定其吸光值,藉以計算細胞的存活率,並推算出其ic50 值’其結果如表三所示。 表二·體外對肝癌腫瘤細胞抑制之測試結果 一 測試樣品 IC50 (gg/ml) 對照組(加入牛樟芝萃取物) Hep 3B 5.121 Hep G2 18.631 喊驗組(加入式2) Hep 3B 0.005 _ Hep G2 1.679 200829234 由表二中可知,藉由4-羥基-2,3-二甲氧基-6-甲基-5 (3,7,11-三甲基-2,6,1〇·十二碳三烯)-2環己烯酮的作用, 其對於Hep 3Β人類肝癌腫瘤細胞之IC5G值降為〇 〇〇5 pg/ml ’對於Hep G2人類肝癌腫瘤細胞之1(:5()值則降為 1479 μΕ/ιη1,相較於牛樟芝萃取混合物所測得之^別值 係低的多,因此可證實牛樟芝萃取物中之私經基_2,3•二甲 氧基_6_曱基-5 ( 3,7,11-三甲基_2,6,1〇-十二碳三烯)_2·環己 烯酉同確實能夠利用於肝癌腫瘤細胞生長之抑制。 實施例5 ·· 體外對肝癌腫瘤細胞辅助治療之活性測試 本測試同樣係根據美國國家癌症研究所的體外篩檢 模式進行測試。首先,取人類肝癌細胞Hep 3Β與Hep G2 ’分別於含有胎牛血清之培養液中培養24小時後,將 增生後之細胞以PBS清洗一次,並以1倍之胰蛋白酶 -EDTA處理細胞,隨後於1,200 i^pm下離心5分鐘,將細 胞沈澱並丟棄上清液。之後加入10 ml的新培養液,輕微 搖晃使細胞再次懸浮。測試前,先於Hep 3B細胞株試驗 加入0.0043 pg/ml Lovastatin,而於Hep G2細胞株試驗加 入0.0017 gg/ml紫杉醇(Taxol),處理細胞72小時,再 將細胞分置於96孔微量盤内,之後分別於每孔内加入〇 pg/ml (對照組),30、10、3、;[、0.3、0.1 與 〇·〇3 pg/ml 實施例1中所分離之4-羥基_2,3_二甲氧基-6-曱基-5 19 200829234 (3,7,11-三甲基-2,6,l〇-十二碳三烯)-2-環己烯酮(試驗 組),於37°C、5% C〇2下培養48小時。其後,於避 光的環境下於每一孔内加入2·5 mg/ml的MTT,反應4 小時後於每一孔内加入100 μΐ的lySis buffer終止反應。 最後以酵素免疫分析儀在570 nm吸光波長下測定其吸 光值,猎以计异細胞的存活率,並推算出其值,其 結果如表四所示。 表四:體外對肝癌腫瘤細胞經紫杉醇輔助治療後抑制之測 試結果 測試樣品 結果 對照組 細胞存活率(%) Hep 3B (0.0043 μβ/πι1 Lovastatin) 61±3 Hep G2 (0.0017 pg/ml Taxol) 81±2 試驗組 1。5〇 (gg/ml) Hep 3B (0.0043 pg/ml Lovastatin+式 2) 0.002 __(0.0017 pg/ml Taxol + 式 2) 0.008 由表四中可知,透過Lovastatin及紫杉醇之協同作 用’ 4-經基_2,3-二甲氧基_6_甲基_5 (3,7,11_三甲基_2,6,1〇-十二碳三烯)-2-環己烯酮對於Hep 3B人類肝癌腫瘤細胞 之1值降為〇·〇〇2 gg/ml,對於Hep G2人類肝癌腫瘤細 胞之1Cso值亦降為約0.008 gg/m卜因此可證實牛樟芝萃 取物中之4_經基_2,3_二曱氧基_6_曱基-5 ( 3,7,11_三曱基 -2,6,1〇_十二碳三烯)-2_環己烯嗣確實能夠利用於肝癌腫瘤 20 200829234 細胞生長之抑制’且在紫杉醇之協同作訂,有更佳之抑 制效果。 實施例6 : 體外抗攝護腺癌腫瘤細胞之活性測試 本測試亦係根據美國國家癌症研究所抗腫瘤藥物篩 檢模式進行’將實施例1中所分離之4-經基-2,3-二甲氧基 曱基_5 (3,7,11_三曱基-2,6,ι〇-十二碳三烯)_2_環己烯酮 化合物,加入LNCaP與DU-145人類攝護腺癌腫瘤細胞 培養液中進行培養,藉以進行腫瘤細胞存活性之測試。 首先將人類攝護腺癌細胞LNCaP與DU-145分別於 含有胎牛企清之培養液中培養24小時。將增生後之細胞 以PBS清洗一次,並以1倍之胰蛋白酶-EDTA處理細胞, 隨後於1,200 rpm下離心5分鐘,將細胞沈澱並丟棄上清 液。之後加入10 ml的新培養液,輕微搖晃使細胞再次懸 浮’再將細胞分置於96孔微量盤内。測試時,分別於每 一孔内加入30、10、3、1與0·3 pg/ml牛樟芝乙醇萃取物 (對照組,未經純化分離之總萃取物)以及30、10、3、1 與0.3 pg/ml由實施例1所分離之4-經基-2,3·二曱氧基_6_ 曱基-5( 3,7,11_三甲基-2,6,10-十二碳三烯)_2_環己烯_(試 驗組),於37°C、5% C02下培養48小時。其後,於 避光的環境下於每一孔内加入2.5mg/ml的MTT,反應4 小時後再於每一孔内加入1〇〇 μΐ的lysis buffer終止反 21 200829234 應。最後以酵素免疫分析儀在57〇nm吸光波長下蜊定其 吸光值,藉以計算細胞的存活率,並推算出其][Cso值, 其結果如表五所示。 表五·體外對攝護腺癌腫瘤細胞抑制之測試結果 _測試樣品 IC50 (pg/ml) 對照組(加入牛樟芝萃取物) 11.491 41.392 2.378
LNCaP ( DU-145 試驗組(加入式2)
LNCaP DU-145___ 1.812 由表五中可知,藉由4-經基-2,3-二曱氧基_6-甲基_5 (3,7,11_三曱基_2,6,1〇_十二碳三烯)-2-環己烯_的作用, 其對於LNCaP人類攝護腺癌腫瘤細胞之IC%值降為2.378 pg/m卜對於DU-145人類攝護腺癌腫瘤細胞之1C%值則 1 降為UUpg/ml,相較於牛樟芝萃取混合物所測得之Ic% 值係低的多,因此可證實牛樟芝萃取物中之4-輕基_2,3_ 二甲氧基_6_曱基-5 ( 3,7,11_三甲基-2,6,10_十二碳三烯) 環己烯酮確實能夠利用於攝護腺癌腫瘤細胞生長之抑制。 實施例7 ·· 體外對攝護腺癌腫瘤細胞輔助治療之活性測試 22 200829234 本測5式同樣係根據美國國家癌症研究所的體外篩檢 模式進行測試。首先,取人類攝護腺癌細胞LNCaP與 DU-145,分別於含有胎牛血清之培養液中培養24小時 後,將增生後之細胞以PBS清洗一次,並以丨倍之胰蛋 白i#-EDTA處理細胞,隨後於ι,2〇〇印㈤下離心$分鐘, 將細胞沈澱並丟棄上清液。之後加入1〇 ml的新培養液, 輕微搖晃使細胞再次懸浮。測試前,先於LNCaP細胞株 試驗加入0.0017 pg/ml紫杉醇,而於du-145胞株試驗加 入0.0043 pg/ml紫杉醇分別處理細胞72小時,再將細胞 分置於96孔微量盤内,之後分別於每孔内加入〇 μδ/ιη1 (對,¾ 組)’ 30、10、3、1、0·3、〇·1 與 〇·〇3 pg/ml 於實施 例1中所分離之4-經基-2,3-二曱氧基各甲基-5 (3,7,11-三曱基-2,6,10_十二碳三烯)-2•環己烯酮(試驗組),於 37°C、5% C〇2下培養48小時。其後,於避光的環境下 於每一孔内加入2.5 mg/ml的MTT,反應4小時後於每一 孔内加入100 μΐ的lysis buffer終止反應。最後以酵素免 疫分析儀在570 nm吸光波長下測定其吸光值,藉以計算 細胞的存活率,並推算出其IC5G值,其結果如表六所示。 表六:體外對攝護腺癌腫瘤細胞經紫杉醇辅助治療後抑 制之測試結果 測試樣品 結果 對照組 細胞存活率(%) LNCaP (0.0017 pg/ml Taxol) 56±3 DU-145 (0.0043 pg/ml Taxol) 7〇±2 23 200829234 IC50 (pg/ml) 0-961 0.515 試驗組 LNCaP (〇.〇〇i7pg/mi Taxol+式 2) DU-145」〇.〇〇43gg/mi Taxol+式 2) 由表六中可知,透過紫杉醇之協同作用,‘經基_2,3_ ^曱氧基_6_曱基_5 ( w i•三曱基_2,6,1〇_十二碳三烯 玉衣己細酌對於LNCaP人類攝護腺癌腫瘤細胞之值降 為0.961 pg/ml,對於DU-145人類攝護腺癌腫瘤細胞之
ICso值亦降為約〇·515 μ§/ιη1,相較於牛樟芝萃取混合物 所測得之IC5〇值係低的多,因此可證實牛樟芝萃取物中 之一4_Γ^_2,3-二甲氧基各曱基m U三甲基-2,6算 十二碳三烯)_2_環己烯_實能夠於攝護腺癌腫瘤細 胞生長之抑制,且在紫杉醇之協同作用下,有更佳之 效果。 實施例8 : 體外抗氧化活性之試驗 一般抗氧化活性n _用人類低密度脂蛋白 (human 10W density lip〇pr〇tdn,肌),加入銅離子(以+ ) 與待測樣柄行氧化反應,檢測既上二狀反應結果後, =維生素E之水雜類她TfGlGx料·、(τ_χ濃度為 2 μΜ時,其效力值訂域雜1()),計算⑽ 氧化活性。 24 200829234 首先準備二次純水(控制組),並配製5 mM磷酸鈉緩衝 溶液(sodium phosphate buffer,SPB )、1 μΜ 與 2 μΜ 的 Trolox (對照組)及40 pg/ml由實施例1中所分離之4-羥基-2,3-二甲 氧基-6-甲基-5 (3,7,11-三甲基_2,6,10_十二碳三烯)-2-環己烯 酋同(試驗組)。利用酵素法測得低密度膽固醇濃度(LDL-C) 後’利用5 mM SPB將LDL稀釋至0.10〜0.25 mg/ml間。取 96孔的石英微量盤,於其中先加入1〇〇 μ1之LDL,再分別加 入前述預定濃度的Trolox及由實施例1中所分離之化合物, 之後再分別加入CuS04溶液以啟動氧化反應(每一 250 μΐ孔 中的銅(II)濃度為5·0μΜ),最後將該微量盤置於酵素免疫 微量盤分析儀(ELISAreader)中進行檢測。酵素免疫微量盤 分析儀檢測波長設為232 nm,溫度設為37°C,偵測時間為 12小時,採樣間隔時間為15分鐘,其結果如表七所示。 表七:體外抗氧化活性之測試钴罢 測試樣品 Tlag(分) △Tlag(分) 效力值 氏0 (控制紙Tlago) 185 1 μΜ Trolox (對照組) 266 81 0.48 2 μΜ Trolox 344 159 LOO 40 pg/mL 式 2 439 208 1.30 註1 · Tlag(分)係指在吸收光波長為234nm下,延滯期叱) 與連鎖期(propagation phase)的交差點;ΔΉ3β(分)係指各測試 樣品Tlag時間與Tiag()時間的差值。 註2 :效力值>〇·5時,表示其具抗氧化作用。 25 200829234 由表七中可知,4_羥基_2,3·二甲氣基甲基4 (3,7,n_ 三甲基-2,6,10-十二碳三烯)-2-環己烯_具有13〇之效力值, 其比具抗氧化能力之標準值〇·5高出甚多,亦即,其具有相 當之抗氧化能力,因此可用作保健食品、飲食品、醫藥品、 化妝品當中之成分,藉由其抗氧化能力翻驗^血管疾病 或避免細胞突變等效用’使對於施用之人體健康產生莫大的 助益。 【圖式簡單說明】 無 【主要元件符號說明】 無 26
Claims (1)
- 200829234 十、申請專利範圍: 1、一種化合物,包括下列結構式:其中,X係氧⑼或硫(s),Y係氧或硫;R!係氫基(H)、 甲基(CH3)或(CH2)m-CH3,& 係氫基、曱基或(CH2)nrCH3, R3係氫基、曱基或或(CH2)m-CH3,m=l〜12 ; η=ι〜12。 2、 如申請專利範圍第1項所述之該化合物,其係分離自牛樟 芝。 3、 如申凊專利範圍第2項所述之該化合物,其係由牛樟芝之 有機溶劑萃取物中所分離。 4如申印專利範圍第3項所述之該化合物,其中該有機溶劑 係選自g曰類、醇類、烧類或齒烧所組成的族群。 5、 如申凊專利範圍第4項所述之該化合物,其中該醇類係乙 醇。 6、 如申請專利範圍第2項所述之該化合物,其係由牛樟芝之 水萃取物中所分離。 7、 如申請專利範圍第1項所述之該化合物,該化合物係4_羥 基-2,3-二甲氧基甲基_5 ( 3,7,11_三曱基_2,6,10_十二碳三 烯)-2-環己烯酮(4-]^(11%€吩-2,3-(^11^1:11〇乂>^6-11^1:1^-5(3,7,11- trimethyl_dodeca-2,6,10-trienyl)-cyclohex-2_enone )。 27 200829234 8、 一種將具有如申請專利範圍第1 S7項所述化合物利用於 抑制乳癌腫瘤細胞生長之應用。 9、 如申請專利範圍第8項所述將該化合物利用於抑制乳癌腫 瘤細胞生長之應用,其中該化合物係分離自牛樟芝。 10、 如中請專利範圍第9項所述將該化合物利用於抑制乳癌 腫瘤細胞生長之應用,其中該化合物係由牛樟芝之有機溶 劑萃取物中所分離。 ,11、如申請專利範圍第10項所述將該化合物利用於抑制乳癌 腫瘤細胞生長之應用,其中該有機溶劑係選自酯類、醇類、 烷類或i烷所組成的族群。 、 12、 如申請專利範圍第n項所述將該化合物利用於抑制乳癌 腫瘤細胞生長之應用,其中該有機溶劑係乙醇。 13、 如申請專利範圍第9項所述將該化合物利用於抑制乳癌 腫瘤細胞生長之應用,其中該化合物係由牛樟芝之水萃取 物中所分離。 14、 如申請專利範圍第8項所述將該化合物利用於抑制乳癌 腫瘤細胞生長之應用,其中該乳癌腫瘤細胞係¥(:17_7或 MDA-MB_231 細胞系。 15、 一種將具有如申請專利範圍第1或7項所述化合物利用 於抑制肝癌腫瘤細胞生長之應用。 16、 如申請專利範圍第15項所述將該化合物利用於抑制肝癌 腫瘤細胞生長之應用,其中該化合物係分離自牛樟芝。 28 200829234 17、 如申請專利範圍第16項所述將該化合物利用於抑制肝癌 腫瘤細胞生長之應用,其中該化合物係由牛樟芝之有機溶 劑萃取物中所分離。 〆 18、 如申請專利範圍第17項所述將該化合物_於抑制肝癌 腫瘤細胞生長之應用,其中該有機溶劑係選自軸、醇類、 炫類或鹵烧所組成的族群。 、 19、 如申請專利範圍第18項所述將該化合物利用於抑制肝 , 細細胞生長之應用,其中該有機溶劑係乙醇。 ° f 20、如申請專利範圍帛16項所述將該化合物利餘抑制 腫瘤細胞生長之應用,其中該化合物係由牛樟芝之水萃取 物中所分離。 Μ 2卜如申请專利範圍第15項所述將該化合物利用於抑制肝 腫瘤細胞生長之應用’其中該肝癌腫瘤細胞係3 ^ Hep G2細胞系。 或 22、 —種將具有如中請專利範圍第i或7項所述化合物利用 ( 於抑制攝護腺癌腫瘤細胞生長之應用。 23、 如申請專利範圍第22項所述將該化合物利用於抑 腺癌腫瘤細胞生長之應用,其中該化合物係分離自牛樟芝 24、 如中請專利範圍第23項所述將該化合物利用於抑 腺癌腫瘤細胞生長之應用,其中該化合物係由牛掉芝之^ 機溶劑萃取物中所分離。 29 200829234 25、 如申請專利範圍第24項所述將該化合物利用於抑制攝護 腺癌腫瘤細胞生長之應用,其中該有機溶劑係選自_類、 醇類、烷類或鹵烷所組成的族群。 曰、、 26、 如申請專利範圍第25項所述將該化合物利用於抑制攝護 腺癌腫瘤細胞生長之應用,其中該有機溶劑係乙醇。ΰ 27、 如申請專利範圍第23項所述將該化合物利用於抑制攝護 腺癌腫瘤細胞生長之應用,其中該化合物係由牛樟芝之水 萃取物中所分離。 28、 如申請專利範圍第22項所述將該化合物利用於抑制攝護 腺癌腫瘤細胞生長之應用,其中該攝護腺癌腫瘤細胞係 LNCaP或DU145細胞系。 29、 如申凊專利範圍第1或7項所述之化合物,其係具抗氧 化活性。 3〇 彻於抑制腫瘤細胞生長之醫藥組成物,包括一有 效j里如申請專利範圍第1項所述之化合物以及一藥學上 可接又之栽體,其中該腫瘤細胞係選自乳癌、肝癌或攝護 腺癌之腫瘤細胞。 31 i 利用於抑制腫瘤細胞生長之醫藥組成物,包括一有 、文背j里如申請專利範圍第7項所述之化合物以及一藥學上 可接又之栽體,其中該腫瘤細胞係選自乳癌、肝癌或攝護 腺癌之腫瘤細胞。
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW096100680A TW200829234A (en) | 2007-01-08 | 2007-01-08 | Antrodia camphorata isophorone extract |
US11/747,407 US7342137B1 (en) | 2007-01-08 | 2007-05-11 | Cyclohexenone compounds from Antrodia camphorata and application thereof |
JP2007126866A JP5085186B2 (ja) | 2007-01-08 | 2007-05-11 | ベニクスノキタケから単離された新規化合物 |
DE102007022161A DE102007022161A1 (de) | 2007-01-08 | 2007-05-11 | neue Cyclohexenonverbindungen aus Antrodia camphorata und deren Anwendung |
GB0709171A GB2445430A (en) | 2007-01-08 | 2007-05-14 | 4-hydroxy-2,3-disubstituted-cyclohex-2-en-1-on-5-yl isoprenoids, extractable from Antrodia camphorata, as anti-tumour & cardiovascular agents, & antioxidant |
KR1020070056701A KR101011616B1 (ko) | 2007-01-08 | 2007-06-11 | 안트로디아 캄포라타로부터 얻은 신규 시클로헥세논 화합물및 그의 적용 |
FR0704175A FR2911133A1 (fr) | 2007-01-08 | 2007-06-12 | Nouveaux composes de cyclohexenone provenant d'antrodia camphorata et application de ceux-ci |
ZA200800150A ZA200800150B (en) | 2007-01-08 | 2008-01-01 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
NZ564913A NZ564913A (en) | 2007-01-08 | 2008-01-04 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
NO20080078A NO20080078L (no) | 2007-01-08 | 2008-01-04 | Nye syklohexononforbindelser fra antrodia comphorata og anvendelser derav |
MYPI20080021A MY144944A (en) | 2007-01-08 | 2008-01-07 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
SG200800098-6A SG144815A1 (en) | 2007-01-08 | 2008-01-07 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
AU2008200063A AU2008200063C1 (en) | 2007-01-08 | 2008-01-07 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
CA2618271A CA2618271C (en) | 2007-01-08 | 2008-01-07 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
BRPI0800401-3A BRPI0800401A (pt) | 2007-01-08 | 2008-01-08 | novos compostos da ciclohexenona a partir da antrodia camphorata e suas aplicações |
ARP080100073A AR064788A1 (es) | 2007-01-08 | 2008-01-08 | Compuestos de ciclohexenona de la antrodia comphorata y usos de los mismos |
EP08250090A EP1942093B1 (en) | 2007-01-08 | 2008-01-09 | Novel cyclohexenone compounds from antrodia camphorata and application thereof |
SI200830296T SI1942093T1 (sl) | 2007-01-08 | 2008-01-09 | Nove cikloheksenonske spojine iz antrodia camphorata in njihove aplikacije |
ES08250090T ES2365888T3 (es) | 2007-01-08 | 2008-01-09 | Compuestos de ciclohexenona novedosos procedentes de antrodia camphorata y sus aplicaciones. |
PT08250090T PT1942093E (pt) | 2007-01-08 | 2008-01-09 | Novos compostos de cyclohexenone a partir de antrodia camphorata e sua aplicação |
AT08250090T ATE509005T1 (de) | 2007-01-08 | 2008-01-09 | Neuartige cyclohexenon-verbindungen aus antrodia camphorata und anwendungen dafür |
DK08250090.1T DK1942093T5 (da) | 2007-01-08 | 2008-01-09 | Hidtil ukendte cyclohexenon-forbindelser fra antrodia camphorata og anvendelse deraf |
PL08250090T PL1942093T3 (pl) | 2007-01-08 | 2008-01-09 | Nowe związki cykloheksenonowe z Antrodia camphorata oraz ich zastosowanie |
CY20111100713T CY1111722T1 (el) | 2007-01-08 | 2011-07-20 | Νεες ενωσεις κυκλοεξενονης απο antrodia camphorata και εφαρμογες αυτων |
HR20110588T HRP20110588T1 (hr) | 2007-01-08 | 2011-08-04 | Novi cikloheksenonski spojevi iz antrodia camphorata i njihova primjena |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW096100680A TW200829234A (en) | 2007-01-08 | 2007-01-08 | Antrodia camphorata isophorone extract |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200829234A true TW200829234A (en) | 2008-07-16 |
TWI330528B TWI330528B (zh) | 2010-09-21 |
Family
ID=38219309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW096100680A TW200829234A (en) | 2007-01-08 | 2007-01-08 | Antrodia camphorata isophorone extract |
Country Status (25)
Country | Link |
---|---|
US (1) | US7342137B1 (zh) |
EP (1) | EP1942093B1 (zh) |
JP (1) | JP5085186B2 (zh) |
KR (1) | KR101011616B1 (zh) |
AR (1) | AR064788A1 (zh) |
AT (1) | ATE509005T1 (zh) |
AU (1) | AU2008200063C1 (zh) |
BR (1) | BRPI0800401A (zh) |
CA (1) | CA2618271C (zh) |
CY (1) | CY1111722T1 (zh) |
DE (1) | DE102007022161A1 (zh) |
DK (1) | DK1942093T5 (zh) |
ES (1) | ES2365888T3 (zh) |
FR (1) | FR2911133A1 (zh) |
GB (1) | GB2445430A (zh) |
HR (1) | HRP20110588T1 (zh) |
MY (1) | MY144944A (zh) |
NO (1) | NO20080078L (zh) |
NZ (1) | NZ564913A (zh) |
PL (1) | PL1942093T3 (zh) |
PT (1) | PT1942093E (zh) |
SG (1) | SG144815A1 (zh) |
SI (1) | SI1942093T1 (zh) |
TW (1) | TW200829234A (zh) |
ZA (1) | ZA200800150B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI383791B (zh) * | 2009-09-09 | 2013-02-01 | Golden Biotechnology Corp | Used to inhibit the growth of gastric cancer tumor cells of the male antler ketone compounds |
TWI383790B (zh) * | 2009-09-09 | 2013-02-01 | Golden Biotechnology Corp | Used to inhibit the growth of oral cancer cells of the cattle Antrodylcyclohexenone compounds |
TWI483718B (zh) * | 2010-09-20 | 2015-05-11 | Golden Biotechnology Corp | 治療肺癌之方法及醫藥組成物 |
TWI559917B (en) * | 2012-11-21 | 2016-12-01 | Golden Biotechnology Corp | Methods and compositions for treating neurodegenerative diseases |
TWI583376B (zh) * | 2013-03-20 | 2017-05-21 | Hui-Ling Zeng | Compounds isolated from Antelroxicus and their use |
TWI637746B (zh) * | 2016-01-20 | 2018-10-11 | 台灣利得生物科技股份有限公司 | 固態培養牛樟芝菌絲體及子實體萃取物之組合物作為腫瘤抑制劑之應用 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI394572B (zh) * | 2007-06-12 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum aurantii Cyclohexenone Compounds in the Preparation of Drugs for the Treatment of Autoimmune Diseases |
TWI394573B (zh) * | 2007-06-14 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection |
CN101333156B (zh) * | 2007-06-27 | 2011-07-20 | 国鼎生物科技股份有限公司 | 牛樟芝环己烯酮化合物的制备方法及其应用 |
TWI394575B (zh) * | 2007-07-09 | 2013-05-01 | Golden Biotechnology Corp | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for the Suppression of Hepatitis B Virus |
JP5203644B2 (ja) * | 2007-07-13 | 2013-06-05 | 國鼎生物科技股▲ふん▼有限公司 | 自己免疫疾病の治療に用いるベニクスノキタケ由来の化合物 |
JP5106935B2 (ja) * | 2007-07-17 | 2012-12-26 | 國鼎生物科技股▲ふん▼有限公司 | 生理的疲労の緩和に用いるベニクスノキタケのシクロヘキサンケトン化合物 |
CN101357883B (zh) * | 2007-07-30 | 2012-09-26 | 国鼎生物科技股份有限公司 | 治疗自体免疫疾病的牛樟芝环己烯酮化合物及医药组成物 |
CN101362679B (zh) * | 2007-08-08 | 2012-05-30 | 国鼎生物科技股份有限公司 | 用于抑制b型肝炎病毒的牛樟芝环己烯酮化合物 |
CN101376624B (zh) * | 2007-08-29 | 2011-06-01 | 国鼎生物科技股份有限公司 | 用于护肝的牛樟芝环己烯酮化合物 |
CN101417934B (zh) * | 2007-10-24 | 2012-04-18 | 国鼎生物科技股份有限公司 | 分离自牛樟芝萃取物的化合物 |
TW201102075A (en) * | 2009-07-09 | 2011-01-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer |
TW201102076A (en) * | 2009-07-09 | 2011-01-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea suppressing growth of tumor cell of osteosarcoma |
TW201109023A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of colorectal cancer |
TWI394566B (zh) * | 2009-09-09 | 2013-05-01 | Golden Biotechnology Corp | Used to inhibit the growth of ovarian cancer tumor cells of the cattle camphor cyclohexene ketone compounds |
TW201109024A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of bladder cancer |
TW201109013A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone chemical compounds of Antrodia cinnamomea for suppressing the growth of the Lymphoma tumor cell |
TW201109014A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of skin cancer |
ES2574606T3 (es) * | 2009-11-26 | 2016-06-21 | National Taiwan University | Una sustancia activa contra el cáncer de Antrodia camphorata, método de preparación de la misma y uso de la misma |
TWI452032B (zh) | 2011-01-21 | 2014-09-11 | Golden Biotechnology Corp | 治療腎病之醫藥組成物 |
US20130158113A1 (en) * | 2011-06-10 | 2013-06-20 | Golden Biotechnology Corporation | Methods and compositions for treating brain cancer |
FR2987264A1 (fr) | 2012-02-23 | 2013-08-30 | Golden Biotechnology Corp | Methodes et compositions pour le traitement des metastases cancereuses |
CN104220083B (zh) * | 2012-03-26 | 2018-11-27 | 国鼎生物科技股份有限公司 | 用于治疗动脉硬化性血管疾病的方法和组合物 |
CN103058846B (zh) * | 2013-01-17 | 2014-07-30 | 福州大学 | 一种源于棘孢曲霉的苯醌衍生物及其应用 |
US20150018296A1 (en) * | 2013-03-15 | 2015-01-15 | Golden Biotechnology Corporation | Therapeutic methods and compositions utilizing cyclohexenone compounds |
TW201521752A (zh) * | 2013-12-05 | 2015-06-16 | Univ Nat Taiwan Normal | 牛樟芝於抗肥胖的應用及其方法 |
EP3984537B1 (en) * | 2013-12-20 | 2024-03-20 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of type 2 mek and erk inhibitors |
CN104522794B (zh) * | 2014-12-04 | 2017-01-11 | 深圳市仁泰生物科技有限公司 | 樟芝解毒饮料及其制备方法 |
PL3240772T3 (pl) * | 2014-12-30 | 2021-06-28 | ONENESS BIOTECH CO., Ltd | Związki z antrodia camphorata, sposoby ich otrzymywania i ich zastosowanie |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3064012A (en) * | 1960-07-20 | 1962-11-13 | Merck & Co Inc | Derivatives of coenzyme q10 |
EP0205576A1 (en) * | 1984-12-17 | 1986-12-30 | Harbor Branch Oceanographic Institution, Inc. | Antiviral and antitumor cyclohexadienone compositions |
TWI226370B (en) * | 2000-02-17 | 2005-01-11 | Food Industry Res & Dev Inst | Isolate of Antrodia camphorata, process for producing a culture of the same and product obtained thereby |
US6767543B2 (en) * | 2000-02-17 | 2004-07-27 | Council Of Agriculture, Executive Yuan | Process for producing a culture of Antrodia camphorata and product obtained thereby |
JP5403844B2 (ja) * | 2004-03-02 | 2014-01-29 | 善笙生物科技股▲分▼有限公司 | AntrodiaCamphorataの菌糸体から得た新規な混合物及び化合物、並びにその使用 |
US7109232B2 (en) * | 2004-03-08 | 2006-09-19 | Simpson Biotech Co., Ltd. | Compounds from Antrodia camphorata having anti-inflammatory and anti-tumor activity |
TW200638867A (en) * | 2005-05-06 | 2006-11-16 | Golden Biotechnology Corp | Incubation and application methods for the culture of antrodia camphorata |
US20070116787A1 (en) * | 2005-11-21 | 2007-05-24 | Chih-Jung Yao | Cancer treatment |
-
2007
- 2007-01-08 TW TW096100680A patent/TW200829234A/zh unknown
- 2007-05-11 DE DE102007022161A patent/DE102007022161A1/de not_active Withdrawn
- 2007-05-11 US US11/747,407 patent/US7342137B1/en active Active
- 2007-05-11 JP JP2007126866A patent/JP5085186B2/ja active Active
- 2007-05-14 GB GB0709171A patent/GB2445430A/en not_active Withdrawn
- 2007-06-11 KR KR1020070056701A patent/KR101011616B1/ko active IP Right Grant
- 2007-06-12 FR FR0704175A patent/FR2911133A1/fr active Pending
-
2008
- 2008-01-01 ZA ZA200800150A patent/ZA200800150B/en unknown
- 2008-01-04 NZ NZ564913A patent/NZ564913A/en not_active IP Right Cessation
- 2008-01-04 NO NO20080078A patent/NO20080078L/no not_active Application Discontinuation
- 2008-01-07 SG SG200800098-6A patent/SG144815A1/en unknown
- 2008-01-07 MY MYPI20080021A patent/MY144944A/en unknown
- 2008-01-07 AU AU2008200063A patent/AU2008200063C1/en active Active
- 2008-01-07 CA CA2618271A patent/CA2618271C/en active Active
- 2008-01-08 AR ARP080100073A patent/AR064788A1/es not_active Application Discontinuation
- 2008-01-08 BR BRPI0800401-3A patent/BRPI0800401A/pt not_active Application Discontinuation
- 2008-01-09 PT PT08250090T patent/PT1942093E/pt unknown
- 2008-01-09 SI SI200830296T patent/SI1942093T1/sl unknown
- 2008-01-09 ES ES08250090T patent/ES2365888T3/es active Active
- 2008-01-09 DK DK08250090.1T patent/DK1942093T5/da active
- 2008-01-09 PL PL08250090T patent/PL1942093T3/pl unknown
- 2008-01-09 EP EP08250090A patent/EP1942093B1/en active Active
- 2008-01-09 AT AT08250090T patent/ATE509005T1/de active
-
2011
- 2011-07-20 CY CY20111100713T patent/CY1111722T1/el unknown
- 2011-08-04 HR HR20110588T patent/HRP20110588T1/hr unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI383791B (zh) * | 2009-09-09 | 2013-02-01 | Golden Biotechnology Corp | Used to inhibit the growth of gastric cancer tumor cells of the male antler ketone compounds |
TWI383790B (zh) * | 2009-09-09 | 2013-02-01 | Golden Biotechnology Corp | Used to inhibit the growth of oral cancer cells of the cattle Antrodylcyclohexenone compounds |
TWI483718B (zh) * | 2010-09-20 | 2015-05-11 | Golden Biotechnology Corp | 治療肺癌之方法及醫藥組成物 |
TWI559917B (en) * | 2012-11-21 | 2016-12-01 | Golden Biotechnology Corp | Methods and compositions for treating neurodegenerative diseases |
TWI583376B (zh) * | 2013-03-20 | 2017-05-21 | Hui-Ling Zeng | Compounds isolated from Antelroxicus and their use |
TWI637746B (zh) * | 2016-01-20 | 2018-10-11 | 台灣利得生物科技股份有限公司 | 固態培養牛樟芝菌絲體及子實體萃取物之組合物作為腫瘤抑制劑之應用 |
Also Published As
Publication number | Publication date |
---|---|
CY1111722T1 (el) | 2015-10-07 |
ATE509005T1 (de) | 2011-05-15 |
GB0709171D0 (en) | 2007-06-20 |
US7342137B1 (en) | 2008-03-11 |
KR20080065218A (ko) | 2008-07-11 |
SG144815A1 (en) | 2008-08-28 |
AU2008200063A1 (en) | 2008-07-24 |
DK1942093T5 (da) | 2012-04-02 |
ZA200800150B (en) | 2009-08-26 |
AU2008200063C1 (en) | 2011-05-19 |
EP1942093B1 (en) | 2011-05-11 |
TWI330528B (zh) | 2010-09-21 |
AU2008200063B2 (en) | 2010-01-07 |
AR064788A1 (es) | 2009-04-22 |
MY144944A (en) | 2011-11-30 |
CA2618271C (en) | 2010-08-31 |
HRP20110588T1 (hr) | 2011-11-30 |
ES2365888T3 (es) | 2011-10-13 |
PT1942093E (pt) | 2011-08-23 |
KR101011616B1 (ko) | 2011-01-27 |
JP5085186B2 (ja) | 2012-11-28 |
CA2618271A1 (en) | 2008-07-08 |
DK1942093T3 (da) | 2011-08-29 |
SI1942093T1 (sl) | 2012-01-31 |
PL1942093T3 (pl) | 2011-10-31 |
DE102007022161A1 (de) | 2008-07-10 |
FR2911133A1 (fr) | 2008-07-11 |
GB2445430A (en) | 2008-07-09 |
JP2008169194A (ja) | 2008-07-24 |
EP1942093A1 (en) | 2008-07-09 |
NZ564913A (en) | 2009-05-31 |
BRPI0800401A (pt) | 2008-08-26 |
NO20080078L (no) | 2008-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI330528B (zh) | ||
TWI335314B (zh) | ||
TWI394575B (zh) | Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for the Suppression of Hepatitis B Virus | |
CN101225066B (zh) | 牛樟芝的环己烯酮萃取物 | |
CN101417934B (zh) | 分离自牛樟芝萃取物的化合物 | |
WO2008086743A1 (fr) | Application d'un extrait d'antrodia cinnamomea pour l'inhibition de la croissance de cellules tumorales | |
TWI394566B (zh) | Used to inhibit the growth of ovarian cancer tumor cells of the cattle camphor cyclohexene ketone compounds | |
TW201212923A (en) | Triterpenoid compounds, benzenoid compounds, and pharmaceutical compositions containing the same | |
TWI302834B (zh) | ||
TW201102075A (en) | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer | |
CN101343247B (zh) | 牛樟芝的环己烯酮萃取物 | |
CN104177240B (zh) | 分离自牛樟芝的化合物、萃取物及其用途 | |
TW201102076A (en) | Cyclohexenone compound of Antrodia cinnomomea suppressing growth of tumor cell of osteosarcoma | |
TWI361687B (zh) | ||
TWI379678B (zh) | ||
TWI379679B (zh) | ||
TWI583376B (zh) | Compounds isolated from Antelroxicus and their use | |
TWI383790B (zh) | Used to inhibit the growth of oral cancer cells of the cattle Antrodylcyclohexenone compounds | |
CN102000046B (zh) | 牛樟芝环己烯酮化合物在制备用于抑制胰脏癌肿瘤细胞生长的药物中的应用 | |
CN101362679B (zh) | 用于抑制b型肝炎病毒的牛樟芝环己烯酮化合物 | |
TW201109024A (en) | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of bladder cancer | |
CN104211627A (zh) | 牛樟芝化合物、萃取物及其用途 | |
CN102232946B (zh) | 牛樟芝环己烯酮化合物在制备用于抑制胃癌肿瘤细胞生长的药物的用途 | |
CN102232944B (zh) | 用于抑制口腔癌肿瘤细胞生长的牛樟芝环己烯酮化合物 | |
CN102232945B (zh) | 牛樟芝环己烯酮化合物在制备用于抑制膀胱癌肿瘤细胞生长的药物的用途 |